Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

Journal article

Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined. Co-administration of histone deacetylase inhibitors, such as vorinostat (VOR), is reported to improve the clinical activity of AZA, but this has not been prospectively studied in patients with AML. Experimental De... Expand abstract

Authors: Craddock, C; Houlton, A; Quek, L; Ferguson, P; Gbandi, E

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: American Association for Cancer Research
• Journal: Clinical Cancer Research
• Volume: 23
• Issue: 21
• Pages: 6430-6440
• Publication date: 2017-08-01
• Acceptance date: 2017-07-26
• DOI: 10.1158/1078-0432.ccr-17-1423
• EISSN: 1557-3265
• ISSN: 1078-0432
• Pmid: 28765326
• Language: English
• Keywords: Tumor Suppressor Protein p53; Mutation; Humans; Histone Deacetylase Inhibitors; Treatment Outcome; Combined Modality Therapy; Middle Aged; Aged; Drug Administration Schedule; Female; Disease-Free Survival; Male; Hydroxamic Acids; Antineoplastic Combined Chemotherapy Protocols; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Adult; Azacitidine; Cyclin-Dependent Kinase Inhibitor p18